Zobrazeno 1 - 10
of 97
pro vyhledávání: ''
Autor:
Cristina Matteo, Giovanni Schininà, Nunziatina Laura Parrinello, Roberta Sciortino, Salvatore Leotta, Giuseppe Milone, Gianna Maria Piccolo, Massimo Zucchetti, Francesco Di Raimondo, Maria Grazia Camuglia, Annalisa Condorelli, Maria Proietto
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:267-270
Relapse at the central nervous system (CNS) in acute myeloid leukemia (AML) carries a dismal prognosis. Treatment options are limited to intrathecal therapy, high-dose cytarabine, high-dose methotrexate, and radiotherapy. Novel strategies are needed.
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Quizartinib, a potent, selective FMS-like tyrosine kinase 3 (FLT3) inhibitor, is currently in phase 3 development for patients with FLT3–internal tandem duplication-mutated acute myeloid leukemia (AML). Acid-reducing agents (ARAs; e.g., pro
Autor:
Tomohiro Uto, Takafumi Suda, Shun Matsuura, Kazuhiro Asada, K. Tanaka, Naoki Inui, Tomoyuki Fujisawa, Noriyuki Enomoto, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Hideki Kusagaya, Dai Hashimoto, Takashi Matsui, Yutaro Nakamura, Hironao Hozumi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:147-153
There remains an unmet clinical need for the control of chemotherapy-induced nausea and vomiting (CINV), particularly in the prevention of nausea and the delayed phase control. We evaluated the efficacy and safety of antiemetic therapy with olanzapin
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:677-684
Sorafenib is a multi-kinase inhibitor for treatment of advanced hepatocellular carcinoma (HCC). Beyond its clinical benefit against advanced HCC, the efficacy and safety of sorafenib chemotherapy are critical concerns. In this study, we addressed the
Publikováno v:
Cancer Chemotherapy and Pharmacology. 79:995-1001
There is little information on tolerability to cisplatin-based chemotherapies in patients with a solitary kidney after nephroureterectomy. We evaluated the impact of having a solitary kidney on tolerability to gemcitabine plus cisplatin (GC) chemothe
Autor:
Jan H. Beumer, Jogarao Gobbru, Josephine Feliciano, Martin J. Edelman, Tao Liu, Miroslav Styblo, Rena G. Lapidus
Publikováno v:
Cancer Chemotherapy and Pharmacology. 78:959-967
KML-001 (sodium metaarsenite) displaces hTERT from the nucleus and is synergistic with cisplatin. This phase I trial tested the tolerability, activity and pharmacology of this combination. Patients with advanced solid tumors that were “platinum sen
Autor:
Fadi Braiteh, Ling Gao, Christopher John Asakiewicz, James J. Lee, Yong Lin, F. Nasroulah, Ding Wang, Archana Chaudhary, Dale R. Shepard, Crystal S. Denlinger, Patricia LoRusso
Publikováno v:
Cancer Chemotherapy and Pharmacology. 78:727-733
The objective of this phase II study was to evaluate the potential of pharmacokinetic (PK) drug–drug interactions between ramucirumab and irinotecan or its metabolite, SN-38, when administered with folinic acid and 5-fluorouracil (FOLFIRI). Patient
Autor:
Marie Perier-Muzet, Luc Thomas, Frédérique Dijoud, Maurice Laville, Gérard Duru, Cécile Teuma, Mona Amini-Adl, Mathilde Nouvier, Denis Fouque, Stéphane Dalle, Solenne Pelletier
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2016, 78 (2), pp.419-26. ⟨10.1007/s00280-016-3086-7⟩
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2016, 78 (2), pp.419-26. ⟨10.1007/s00280-016-3086-7⟩
International audience; PURPOSE: Vemurafenib (VMF) is a B-RAF inhibitor used in the treatment of B-RAF-V600-mutant metastatic melanomas. Reports of acute kidney injury (AKI) in patients treated with VMF are scarce. METHODS: To investigate the inciden
Autor:
Yoshiro Nakahara, Kageaki Watanabe, Yusuke Takagi, Yusuke Okuma, Satoshi Takahashi, Tatsuru Okamura, Makiko Yomota, Yukio Hosomi, Makoto Nagamata, Kuniko Sunami, Tsuneo Shimokawa
Publikováno v:
Cancer Chemotherapy and Pharmacology. 77:559-564
A vitamin B12 supplement is required in pemetrexed single agent therapy. Intramuscular administration is the method of choice; however, oral administration is simpler and easier and may be sufficiently effective. We conducted a Phase II study to eval
Autor:
Kevin P. Bethke, Oukseub Lee, Kara Kenney, Subhashini Allu, Irene Helenowski, Denise M. Scholtens, David Ivancic, Ali Shidfar, Nora M. Hansen, Robert T. Chatterton, Miguel Muzzio, Seema A. Khan, Megan E. Sullivan
Publikováno v:
Cancer Chemotherapy and Pharmacology. 76:1235-1246
Women at high risk of breast cancer and those with carcinoma in situ need non-toxic, well-tolerated preventive interventions. One promising approach is drug delivery through the breast skin (local transdermal therapy, LTT). Our goal was to test novel